Comparison of the steady-state pharmacokinetics of nefazodone after administration of 200 mg twice daily or 400 mg once daily in the morning or evening

British Journal of Clinical Pharmacology

Volumn 41, Issue 1, 1996, Pages 21-27

  Marathe, Punit H ^a   Lee, James S ^a   Greene, Douglas S ^a   Barbhaiya, Rashmi H ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Antidepresive agents; Nefazodone; Pharmacokinetics; Steady state

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; DRUG METABOLITE; HYDROXYNEFAZODONE; NEFAZODONE; TRIAZOLEDIONE; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CIRCADIAN RHYTHM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERANCE; HEADACHE; HOT FLUSH; HUMAN; HUMAN EXPERIMENT; MALE; NAUSEA; NORMAL HUMAN; PHARMACOKINETICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VERTIGO; VOLUNTEER; XEROSTOMIA;

EID: 0030033701     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2125.1996.tb00154.x     Document Type: Article

References (17)

1. Eison AS, Eison MS, Torrente JR, Wright RN, Yucca FD. Nefazodone: preclinical pharmacology of a new antidepressant. Psycopharmacol Bull 1989; 25: 219-221.
2. Taylor, DP, Smith DW, Hyslop DK, Riblet LA, Temple Jr DL. Receptor binding and atypical antidepressant drug discovery. In Receptor binding in drug research, ed R.A. O'Brien, New York: Marcel Dekker, 1986: 151-165.
3. Hyslop DK, Allen LE, Taylor DP. Triazolo antidepressants do not inhibit monoamine oxidase. Drug Dev Res 1988; 12: 77-79.
4. Kaul S, Shukla UA, Barbhaiya RH. Nonlinear pharmacokinetics of nefazodone after escalating single and multiple oral doses. J Clin Pharmacol 1995; 35: 830-834.
5. Mayol RF, Cole CA, Luke GM, Colson KL, Kerns EH. Characterization of the metabolites of the antidepressant drug nefazodone in human urine and plasma. Drug Metab Disp 1994; 22: 304-311.
6. Buch AB, Shukla UA, Pittman KA, Barbhaiya RH. Pharmacokinetics of nefazodone in extensive (EM) and poor (p.m.) metabolizers of dextromethorphan. Pharm Res 1993; 10: S134.
7. Schmid B, Bircher MD, Preisig R, Kupfer A. Polymorphic dextromethorphan metabolism: co-segregation of oxidative o-demethylation with debrisoquin hydroxylation. Clin Pharmacol Ther 1985; 38: 618-624.
8. Franc JE, Duncan GF, Farmen RH, Pittman KA. High-performance liquid chromatographic method for the determination of nefazodone and its metabolites in human plasma using laboratory robotics. J Chromatogr 1991; 570: 129-138.
9. Gibaldi M, Perrier D. Pharmacokinetics Second Edition, New York: Marcel Dekker, 1982.
10. Riegelman S, Collier P. An application of statistical moment theory to the evaluation of in vivo dissolution time and absorption time. J Pharmacokinet Biopharm 1980; 8: 509-534.
11. Gill JL. Design and analysis of experiments in the animal and medical sciences. The Iowa State University Press, Ames, IA, 1978: 179-182.
12. Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm 1987; 15: 657-680.
13. Hollander M, Wolfe DA. Nonparametric Statistical Methods. John Wiley and Sons, New York, 50-53.
14. Box GEP, Cox DR. Analysis of transformations. J Roy Stat Soc 1964 (Ser B); 265: 211-252.
15. Snedecor GW, Cochran WG. Statistical methods, Seventh Edition, Iowa State University Press, Ames, IA, 1980: 253-254.
16. Dockens R, Greene D, Barbhaiya R. Lack of food effect on the bioavailability of nefazodone tablets. Biopharm Drug Disp (in press).
17. Barbhaiya RH, Shukla UA, Kroboth PD, Greene DS. Coadministration of nefazodone and benzodiazepines II: A pharmacokinetic interaction study of triazolam. J Clin Psychopharmacol 1995; 15: 320-326..